FENNEC PHARMACEUTICALS INC. Logo

FENNEC PHARMACEUTICALS INC.

Biopharmaceutical company focused on preventing hearing loss in pediatric oncology.

FENC | US

Overview

Corporate Details

ISIN(s):
CA31447P1009
LEI:
Country:
United States of America
Address:
PO BOX 13628, 27709 RESEARCH TRIANGLE PARK

Description

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of its proprietary product, PEDMARK®. PEDMARK is a unique formulation of sodium thiosulfate designed to reduce the risk of ototoxicity (permanent hearing loss) associated with cisplatin chemotherapy. The product is specifically indicated for pediatric patients with localized, non-metastatic solid tumors. The company's core mission is to address this significant unmet medical need in pediatric oncology, preventing lifelong hearing loss in children undergoing cancer treatment.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all FENNEC PHARMACEUTICALS INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for FENNEC PHARMACEUTICALS INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for FENNEC PHARMACEUTICALS INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Acurx Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing a new class of antibiotics for priority pathogens.
United States of America
ACXP
Adaptimmune Therapeutics PLC Logo
Commercial-stage biopharma developing TCR T-cell therapies for solid tumors.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops IgY-based immune antibodies as alternatives to vaccines and antibiotics.
South Korea
179530
ADC Therapeutics SA Logo
Commercial-stage biotech developing antibody-drug conjugates for cancer therapy.
United States of America
ADCT
Addex Therapeutics Ltd. Logo
Clinical-stage biopharma developing allosteric modulators for neurological disorders.
Switzerland
ADXN
ADIAL PHARMACEUTICALS, INC. Logo
A clinical-stage biopharma developing genetically targeted therapies for addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Develops allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET
Adlai Nortye Ltd. Logo
A clinical-stage biopharma firm developing cancer immunotherapies and RAS-targeting drugs.
United States of America
ANL
ADMA BIOLOGICS, INC. Logo
Biopharmaceutical company that develops and manufactures plasma-derived biologics.
United States of America
ADMA
Adverum Biotechnologies, Inc. Logo
A clinical-stage company developing gene therapies for ocular diseases.
United States of America
ADVM

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.